SCHEMBL32677974

SCHEMBL32677974

COC(=O)C1CCC(n2ccccc2=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.51
▸ RAB9A P51151 5/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ HTT P42858 1/20 0.44
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ PKM P14618 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677973 1.00 ALDH1A1 (0.51) ALDH1A1RAB9ANPC1HSD17B10SMN1; SMN2
SCHEMBL8269036 0.76 MEN1 (0.40) ALDH1A1SMN1; SMN2MAPTGAATSHR
SCHEMBL15797759 0.73 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A
SCHEMBL30558157 0.73 KDM5A (0.39) ALDH1A1SMN1; SMN2KDM4ECYP3A4CYP2C9
SCHEMBL25379016 0.73 SMN1; SMN2 (0.38) ALDH1A1RAB9ANPC1HSD17B10SMN1; SMN2
SCHEMBL30442517 0.73 SMN1; SMN2 (0.38) ALDH1A1RAB9ANPC1HSD17B10SMN1; SMN2
SCHEMBL30531972 0.73 DRD2 (0.51) KMT2A
SCHEMBL26319532 0.73 DRD2 (0.51) KMT2A
SCHEMBL31099589 0.73 MAPK1 (0.38) IRAK4
SCHEMBL30442514 0.72 LMNA (0.40) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF HUTCHMED LTD (CN) 2026-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055108-A1 TRIAZINE COMPOUNDS AND USES THEREOF CBR1, CNR1, CBR3 ALDH1A1 1308/4885RAB9A 2056/4885NPC1 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback